De-escalation of five-year adjuvant endocrine therapy in patients with estrogen receptor-low positive (immunohistochemistry staining 1%-10%) breast cancer: Propensity-matched analysis from a prospectively maintained cohort.

Yu-Wen CaiZhi-Ming ShaoJinha Yu

Published in: Cancer (2022)

Short-term endocrine therapy for 2 to 3 years might be an alternative for patients who have ER-low positive breast cancer instead of the standard 5 years of treatment.

Keyphrases

estrogen receptor
positive breast cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
early stage
prognostic factors
clinical trial
young adults
open label
patient reported outcomes
patient reported
replacement therapy
smoking cessation